Sable Therapeutics Announces Exclusive Worldwide Licensing Agreement with Columbia University to Develop Novel Polycation Nanomedicines for the Treatment of Obesity

Posted on by

Sable Therapeutics, a portfolio company of Turret Capital Management, announces licensing agreement with Columbia University NEW YORK, Aug. 9, 2024 /PRNewswire/ — Sable Therapeutics, an innovative early stage drug development company focused on pioneering fat reduction therapies, today…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.